Alpha Tau to Participate in May Investor Conferences
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, today announced that CFO Raphi Levy will present at the following investor conferences in May 2024.
2024年5月1日，耶路撒冷（全球新聞社） - Alpha Tau Medical Ltd.（以下簡稱Alpha Tau或公司）（納斯達克證券代碼：DRTS、DRTSW），開發創新Alpha DaRt α放射線癌症治療方案的開發者，今日宣佈公司CFO Raphi Levy將於2024年5月在以下投資者會議上發言。
| Event: | Guggenheim Securities Radiopharmaceuticals Day |
| Format: | Presentation |
| Date: | May 13, 2024 |
| Time: | 11:30AM ET |
| Location: | New York, NY |
| 活動： | 高盛證券放射性藥物日 |
| 格式： | 介紹 |
| 日期： | 2024年5月13日 |
| 時間： | 美東時間上午11:30 |
| 位置： | 關於Veeva Systems |
| Event: | H.C. Wainwright 2ndAnnual BioConnect Investor Conference |
| Format: | Fireside Chat |
| Date: | May 20, 2024 |
| Time: | 2PM ET |
| Location: | New York, NY |
| 活動： | H.C. Wainwright 2ndBioConnect年度投資者會議 |
| 格式： | 爐邊談話 |
| 日期： | 2024年5月20日 |
| 時間： | 美東時間下午2點 |
| 位置： | 關於Veeva Systems |
Mr. Levy will also be available for 1x1 investor meetings at the conferences. Please reach out to your Guggenheim Securities and H.C. Wainwright representatives to schedule.
Levy先生還將在會議上與投資者進行一對一會議。請聯繫高盛證券和H.C. Wainwright的代表安排會議。
About Alpha Tau Medical Ltd.
關於Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
Alpha Tau成立於2016年，是一家以色列醫療器械公司，專注於Alpha DaRt用於固體腫瘤的研究、開發和潛在商業化。這項技術最初由以色列特拉維夫大學的Itzhak Kelson教授和Yona Keisari教授開發。
About Alpha DaRT
關於Alpha DaRT
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Alpha DaRt（擴散α放射線治療）旨在通過腫瘤內徑流注射鐳-224載藥源，使固體腫瘤獲得高效的和符合條件的α輻照。當鐳衰變時，低壽命子核素從源中釋放並擴散，同時釋放高能α粒子，以達到摧毀腫瘤的目的。由於α放射性原子僅擴散短距離，Alpha DaRt主要針對腫瘤，以保護周圍健康組織。
Investor Relations Contact:
投資者關係聯繫人：
IR@alphatau.com
IR@alphatau.com